Changeflow GovPing Healthcare Diagnostica Stago STA Liatest D-Di Recall — Pos...
Urgent Enforcement Amended Final

Diagnostica Stago STA Liatest D-Di Recall — Positive Bias Issue

Favicon for changeflow.com FDA: Device Recalls Class II
Filed
Detected
Email

Summary

FDA issued Class II recall Z-1585-2026 for Diagnostica Stago's STA Liatest D-Di assay kits (REF 00515). Investigations confirmed a positive bias in D-Dimer measurements across the entire analytical range after customer complaints. The affected products were distributed US nationwide and internationally to Canada, Singapore, Guam, Japan, South Korea, and Russia.

What changed

Diagnostica Stago initiated a voluntary Class II recall for its STA Liatest D-Di immuno-turbidimetric assay after confirmed positive measurement bias in D-Dimer results. The recall applies to catalog number REF 00515 distributed worldwide including US nationwide and Canada, Singapore, Guam, Japan, South Korea, and Russia.

Laboratories and healthcare facilities using this D-Dimer assay should immediately identify affected inventory, quarantine products, and contact the manufacturer for guidance on replacement or resolution. Results from affected kits may be falsely elevated, which could impact clinical decision-making for thrombotic risk assessment and other diagnostic uses.

What to do next

  1. Identify and quarantine affected STA Liatest D-Di kit inventory (REF 00515)
  2. Discontinue use of potentially biased D-Dimer assay until issue resolved
  3. Contact Diagnostica Stago for replacement or resolution guidance

Archived snapshot

Apr 11, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Diagnostica Stago, Inc.

Device Recalls (Class II)

← All Device Recalls (Class II) Class II Z-1585-2026 · 20260325 · Ongoing

Product

Brand Name: STA Liatest D-Di Product Name: STA Liatest D-Di Model/Catalog Number: REF 00515 Product Description: The STA¿ - Liatest ¿ D-Di kit is an immuno-turbidimetric assay for the quantitati...

Reason for Recall

After receiving customer complaints, investigations confirmed the presence of a positive bias in D-Dimer measurements throughout the entire analytical range.

Distribution

Worldwide distribution - US Nationwide and the countries of Canada, Singapore, Guam, Japan, South Korea, and Russia.

Source: openFDA Enforcement API

Get daily alerts for FDA: Device Recalls Class II

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Filed
March 25th, 2026
Instrument
Enforcement
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
Recall Z-1585-2026

Who this affects

Applies to
Healthcare providers Manufacturers Medical device makers
Industry sector
3345 Medical Device Manufacturing
Activity scope
D-Dimer assay testing Diagnostic immunoassay In vitro diagnostics
Geographic scope
United States US

Taxonomy

Primary area
Medical Devices
Operational domain
Clinical Operations
Compliance frameworks
GxP
Topics
Public Health Healthcare

Get alerts for this source

We'll email you when FDA: Device Recalls Class II publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!